Treatment with FXR ligands, either by intraperitoneal (i.p.)injection or oral administration, can reduce the triglyceride level in liver tissue, resulting in the alleviation of fat accumulation in liver15, 16, 19, 20, suggesting the therapeutic effects of FXR agonists in NAFLD. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.